Lakewood-Amedex Biotherapeutics Inc (LABT)

$2.30 +0.14 (6.48%)
Market Cap 5.12M
Revenue (ttm) 0.00
Net Income (ttm) -3.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 0.90
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 102,100
Avg Vol 1,841,867
Day's Range N/A - N/A
Shares Out 2.37M
Stochastic %K 62%
Beta N/A
Analysts Strong Buy
Price Target $12.00

Company Profile

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex In...

Industry: Biotechnology
Sector: Healthcare
Phone: 941 225 2515
Address:
8031 Cooper Creek Blvd., Suite 103, University Park, United States
JimmyOcarri
JimmyOcarri Aug. 17 at 7:52 PM
$NCRA $LABT $FEMY $ISPC $ZNB piece
0 · Reply
DAKZ18
DAKZ18 Aug. 17 at 1:10 AM
$LABT I like.
0 · Reply
Doxtator
Doxtator Aug. 14 at 7:43 PM
$LABT Shares available to short on Fidelity… if you are into that kind of thing.
1 · Reply
Doxtator
Doxtator Aug. 14 at 5:13 PM
$LABT You can Vote now. I own more shares that the Executives and Board combined. Vote Abstain for directors. This is the slate that approved reverse split months into an IPO and want another one. Have them add value instead of destroy it… they get re-elected anyway, becuase they’re is no option for ‘against.’ Down the line vote NO. This is a team that has completely destroyed shareholder value and these proposals are to increase shares available for excutive compensation and DILUTE existing shareholders. This is a team that lost 1 million dollars to a crypto ‘scam’ in Q4 2024. SEC filings continue to show errors. The CEO doesn’t even own any shares. Zero. Think the proposals have shareholder interest in mind? They don’t. Abstain on the directors and “No” down the line. They want to fund thier salaries with shareholder dilution and reverse splits to stay compliant. Send a message to show up to work and add value. Right now this management team is a net negative.
0 · Reply
Doxtator
Doxtator Aug. 13 at 7:12 PM
$LABT Lakewood-Amedex is sitting on an additional shelved indication. In 2013 it reported Bisphosphocin efficacy in preclinical burn wound models and presented ICAAC data showing Nu-3 killed bacteria encased in biofilm in vitro. The company’s own Future Microbiology review in 2015 describes evaluations in animal models of Pseudomonas burn wound infections. The burn program hasn’t advanced since. Burn is where Bisphosphocin properties matter. A significant portion of burn wound infections involve MDR or XDR organisms, and a large portion of burn isolates form biofilm. Much of that population is metabolically dormant, part of why conventional antibiotics fail and where membrane-disrupting agent might have an edge. NIAID runs preclinical infection models free for industry. CARB-X and BARDA fund exactly this. It seems like it would make more sense to actually advance AMR programs than to just issue a Press Release commenting on them.
0 · Reply
Doxtator
Doxtator Aug. 12 at 9:41 PM
$LABT Kelvin Cooper, PhD... Ranked Top 5 in the world... Elite. Personally, I wouldn't want to be ranked in this category though.
0 · Reply
hiddenwolf
hiddenwolf Aug. 11 at 2:07 PM
$NVTS 👀👀👀 $LABT $RUM $RKLB $RIOT
0 · Reply
Doxtator
Doxtator Aug. 10 at 5:38 PM
$LABT Cost to borrow has been elevated above 700% for a while, first I’ve seen above 800% though.
0 · Reply
LargeSodaDrinker
LargeSodaDrinker Aug. 7 at 3:01 AM
$LABT Yeah you fools always lie.... When it goes up, you'll magically claim you had a long position too....
1 · Reply
TurdSniper
TurdSniper Aug. 7 at 12:18 AM
$LABT Looking to short this turd tomorrow ⬇💩
0 · Reply
Latest News on LABT
Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up Today?

2026-07-22T13:26:58.000Z - 27 days ago

Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up Today?

Lakewood-Amedex announces resistance data for Nu-3

2026-07-22T12:12:25.000Z - 4 weeks ago

Lakewood-Amedex announces resistance data for Nu-3

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Jul 22, 2026, 8:02 AM EDT - 4 weeks ago

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Lakewood-Amedex announces preclinical data from Phase 2a clinical trial

2026-07-15T12:10:36.000Z - 5 weeks ago

Lakewood-Amedex announces preclinical data from Phase 2a clinical trial

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Jul 15, 2026, 8:02 AM EDT - 5 weeks ago

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Lakewood-Amedex supports reintroduction of PASTEUR act

2026-07-07T12:10:31.000Z - 6 weeks ago

Lakewood-Amedex supports reintroduction of PASTEUR act

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Jul 7, 2026, 8:02 AM EDT - 6 weeks ago

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.

Jun 25, 2026, 8:02 AM EDT - 7 weeks ago

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.

Lakewood-Amedex Biotherapeutics announces new patent in Australia

2026-06-22T12:13:49.000Z - 2 months ago

Lakewood-Amedex Biotherapeutics announces new patent in Australia

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections

Jun 22, 2026, 8:02 AM EDT - 2 months ago

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections

Lakewood-amedex Biotherapeutics Inc trading halted, news pending

2026-06-18T23:52:08.000Z - 2 months ago

Lakewood-amedex Biotherapeutics Inc trading halted, news pending

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum

Jun 16, 2026, 8:02 AM EDT - 2 months ago

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum

Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says

2026-05-29T18:11:40.000Z - 2 months ago

Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says

Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper

2026-05-29T18:05:31.000Z - 2 months ago

Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper

Lakewood-Amedex Biotherapeutics issued two new patents

2026-05-27T14:34:25.000Z - 2 months ago

Lakewood-Amedex Biotherapeutics issued two new patents

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers

May 27, 2026, 8:02 AM EDT - 3 months ago

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3

2026-05-18T12:12:33.000Z - 3 months ago

Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers

May 18, 2026, 8:02 AM EDT - 3 months ago

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

May 12, 2026, 8:02 AM EDT - 3 months ago

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

Lakewood-Amedex Biotherapeutics’ lead candidate in foot ulcers shows efficacy

2026-05-01T12:13:42.000Z - 3 months ago

Lakewood-Amedex Biotherapeutics’ lead candidate in foot ulcers shows efficacy

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

Apr 28, 2026, 7:33 AM EDT - 4 months ago

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

ENVB

Lakewood-Amedex Biotherapeutics Inc. Common Stock trading halted, volatility trading pause

2026-04-27T13:56:19.000Z - 4 months ago

Lakewood-Amedex Biotherapeutics Inc. Common Stock trading halted, volatility trading pause

Lakewood-Amedex Biotherapeutics Inc. Common Stock trading resumes

2026-04-27T13:44:15.000Z - 4 months ago

Lakewood-Amedex Biotherapeutics Inc. Common Stock trading resumes

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"

Apr 23, 2026, 10:42 AM EDT - 4 months ago

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"

Lakewood-Amedex Biotherapeutics, Biotech Developing Novel Locally Delivered Antimicrobials for Resistant Infections and Chronic Wounds, Files for Nasdaq Capital Market IPO

Jan 9, 2026, 5:38 PM EST - 7 months ago

Lakewood-Amedex Biotherapeutics, Biotech Developing Novel Locally Delivered Antimicrobials for Resistant Infections and Chronic Wounds, Files for Nasdaq Capital Market IPO

Lakewood-Amedex Biotherapeutics IPO Registration Document (S-1)

Jan 9, 2026, 5:28 PM EST - 7 months ago

Lakewood-Amedex Biotherapeutics IPO Registration Document (S-1)

Micro-cap biotech Lakewood-Amedex Biotherapeutics files for a Nasdaq direct listing

Jan 9, 2026, 3:33 PM EST - 7 months ago

Micro-cap biotech Lakewood-Amedex Biotherapeutics files for a Nasdaq direct listing

JimmyOcarri
JimmyOcarri Aug. 17 at 7:52 PM
$NCRA $LABT $FEMY $ISPC $ZNB piece
0 · Reply
DAKZ18
DAKZ18 Aug. 17 at 1:10 AM
$LABT I like.
0 · Reply
Doxtator
Doxtator Aug. 14 at 7:43 PM
$LABT Shares available to short on Fidelity… if you are into that kind of thing.
1 · Reply
Doxtator
Doxtator Aug. 14 at 5:13 PM
$LABT You can Vote now. I own more shares that the Executives and Board combined. Vote Abstain for directors. This is the slate that approved reverse split months into an IPO and want another one. Have them add value instead of destroy it… they get re-elected anyway, becuase they’re is no option for ‘against.’ Down the line vote NO. This is a team that has completely destroyed shareholder value and these proposals are to increase shares available for excutive compensation and DILUTE existing shareholders. This is a team that lost 1 million dollars to a crypto ‘scam’ in Q4 2024. SEC filings continue to show errors. The CEO doesn’t even own any shares. Zero. Think the proposals have shareholder interest in mind? They don’t. Abstain on the directors and “No” down the line. They want to fund thier salaries with shareholder dilution and reverse splits to stay compliant. Send a message to show up to work and add value. Right now this management team is a net negative.
0 · Reply
Doxtator
Doxtator Aug. 13 at 7:12 PM
$LABT Lakewood-Amedex is sitting on an additional shelved indication. In 2013 it reported Bisphosphocin efficacy in preclinical burn wound models and presented ICAAC data showing Nu-3 killed bacteria encased in biofilm in vitro. The company’s own Future Microbiology review in 2015 describes evaluations in animal models of Pseudomonas burn wound infections. The burn program hasn’t advanced since. Burn is where Bisphosphocin properties matter. A significant portion of burn wound infections involve MDR or XDR organisms, and a large portion of burn isolates form biofilm. Much of that population is metabolically dormant, part of why conventional antibiotics fail and where membrane-disrupting agent might have an edge. NIAID runs preclinical infection models free for industry. CARB-X and BARDA fund exactly this. It seems like it would make more sense to actually advance AMR programs than to just issue a Press Release commenting on them.
0 · Reply
Doxtator
Doxtator Aug. 12 at 9:41 PM
$LABT Kelvin Cooper, PhD... Ranked Top 5 in the world... Elite. Personally, I wouldn't want to be ranked in this category though.
0 · Reply
hiddenwolf
hiddenwolf Aug. 11 at 2:07 PM
$NVTS 👀👀👀 $LABT $RUM $RKLB $RIOT
0 · Reply
Doxtator
Doxtator Aug. 10 at 5:38 PM
$LABT Cost to borrow has been elevated above 700% for a while, first I’ve seen above 800% though.
0 · Reply
LargeSodaDrinker
LargeSodaDrinker Aug. 7 at 3:01 AM
$LABT Yeah you fools always lie.... When it goes up, you'll magically claim you had a long position too....
1 · Reply
TurdSniper
TurdSniper Aug. 7 at 12:18 AM
$LABT Looking to short this turd tomorrow ⬇💩
0 · Reply
kellyc09
kellyc09 Aug. 6 at 6:26 PM
$LABT Not sure when but just feel this stock is ready for a massive run. Had a few false breakouts but just seems like it’s being tested. Some PR would help
0 · Reply
TheSqueezeKingdom
TheSqueezeKingdom Aug. 5 at 3:33 PM
$LABT PR coming any moment, any day, any minute…and when it does, we’ll be selling at $6.50+ to FOMO chasers w/o the patience to get in low, exhibit patience, and reap the rewards.
1 · Reply
TheSqueezeKingdom
TheSqueezeKingdom Aug. 5 at 3:12 PM
$JLHL $LABT & $KIDZ UP NEXT
0 · Reply
TheSqueezeKingdom
TheSqueezeKingdom Aug. 5 at 2:36 PM
$LABT easy trip+
0 · Reply
therealrayfinkle
therealrayfinkle Aug. 5 at 1:58 PM
$LABT 0 shares available to short at 776%? Am I seeing that correct?
1 · Reply
missrosie
missrosie Aug. 5 at 1:13 PM
$LABT 👀
0 · Reply
TurdSniper
TurdSniper Aug. 5 at 12:35 PM
$LABT Looks like a fake premarket pump on this turd 💩
0 · Reply
TheSqueezeKingdom
TheSqueezeKingdom Aug. 5 at 12:25 PM
Now onto our $LABT squeeze to $6+
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 5 at 12:20 PM
$LABT Thin
0 · Reply
TraderBuckNKY
TraderBuckNKY Aug. 4 at 5:26 PM
$LABT ...?....
0 · Reply
m3gray
m3gray Aug. 4 at 5:24 PM
$LABT PR coming AH
0 · Reply
stonksandchuckle
stonksandchuckle Aug. 4 at 5:16 PM
$LABT lets go for a ride?
0 · Reply